Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M149,116Revenue $M12,927Net Margin (%)29.8Z-Score20.4
Enterprise Value $M145,514EPS $1.5Operating Margin %38.8F-Score6
P/E(ttm))39.2Cash Flow Per Share $0Pre-tax Margin (%)38.4Higher ROA y-yN
Price/Book26.210-y EBITDA Growth Rate %18.8Quick Ratio1.0Cash flow > EarningsY
Price/Sales11.45-y EBITDA Growth Rate %19.6Current Ratio1.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %7.3ROA % (ttm)38.3Higher Current Ratio y-yN
Dividend Yield %1.3Insider Buy (3m)0ROE % (ttm)69.3Less Shares Outstanding y-yY
Payout Ratio %45.0Shares Outstanding M2,650ROI % (ttm)69.1Gross Margin Increase y-yY

Gurus Latest Trades with NVO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVOKen Fisher 2015-03-31 Reduce-0.03%$41.9 - $54.68
($46.05)
$ 57.1619%Reduce -2.91%12,660,235
NVOMario Gabelli 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 57.1619%Reduce -0.30%6,700
NVORuane Cunniff 2014-09-30 Reduce-0.02%$43.9 - $49.03
($46)
$ 57.1620%Reduce -52.87%75,642
NVORuane Cunniff 2014-06-30 Reduce-0.02%$42.28 - $46.52
($44.12)
$ 57.1623%Reduce -33.85%160,492
NVORuane Cunniff 2014-03-31 Reduce-0.01%$36.722 - $48.23
($42.37)
$ 57.1626%Reduce -21.98%242,630
NVORuane Cunniff 2013-12-31 Add0.02%$32.72 - $36.886
($34.84)
$ 57.1639%Add 58.71%310,970
NVORuane Cunniff 2013-06-30 Buy 0.04%$30.11 - $35.33
($33.29)
$ 57.1642%New holding34,640
NVOMario Gabelli 2013-03-31 Reduce$32.24 - $38.86
($34.93)
$ 57.1639%Reduce -60.32%1,734
NVOKen Fisher 2012-06-30 Add1.01%$25.98 - $30.38
($28.44)
$ 57.1650%Add 519.97%2,786,828
NVOMario Gabelli 2011-12-31 Add$18.92 - $23.05
($21.5)
$ 57.1662%Add 66.87%5,590
NVOKen Fisher 2011-06-30 Add0.06%$23.4 - $26.29
($24.91)
$ 57.1656%Add 68.56%456,434
NVOJohn Keeley 2011-06-30 Sold Out -0.01%$23.4 - $26.29
($24.91)
$ 57.1656%Sold Out0
NVOMario Gabelli 2011-06-30 Reduce$23.4 - $26.29
($24.91)
$ 57.1656%Reduce -21.18%3,350
NVOKen Fisher 2011-03-31 Buy 0.09%$22.16 - $25.59
($23.8)
$ 57.1658%New holding270,785
NVOJohn Keeley 2010-12-31 Buy 0.01%$18.2 - $22.43
($20.77)
$ 57.1664%New holding2,780
NVOVanguard Health Care Fund 2010-09-30 Sold Out -0.19%$16.23 - $19.85
($17.64)
$ 57.1669%Sold Out0
NVOMario Gabelli 2010-09-30 Reduce$16.23 - $19.85
($17.64)
$ 57.1669%Reduce -28.77%4,420
NVOVanguard Health Care Fund 2010-06-30 Reduce-0.08%$14.8 - $17.06
($15.97)
$ 57.1672%Reduce -42.86%400,000
NVOMario Gabelli 2010-06-30 Reduce$14.8 - $17.06
($15.97)
$ 57.1672%Reduce -56.26%6,205
NVOTom Gayner 2010-03-31 Add0.31%$12.77 - $15.83
($14.23)
$ 57.1675%Add 39.04%231,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVO: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about NVO :

    Quarterly/Annual Reports about NVO:

      News about NVO:

      Articles On GuruFocus.com
      Additional Changes to the Nintai Portfolio Apr 08 2015 
      Probability and Magnitude in Investing Apr 02 2015 
      Nintai Returns: Q1 2015 Apr 01 2015 
      These High-Quality European Dividend Payers Could Benefit From A Rising Dollar Mar 18 2015 
      To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
      Guru Stocks at 52-Week Lows: BABA, NVO, PCLN, ING, EMR Feb 09 2015 
      Examining The Three Largest Guru Portfolios Oct 24 2014 
      Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 
      Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
      Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 


      More From Other Websites
      Business Highlights Apr 23 2015
      Economic Sentiment up in the Eurozone: EWG up 0.88%, FEZ up 0.46% Apr 22 2015
      Novo launches Saxenda in US, sees more launches in 2015 Apr 22 2015
      Novo Nordisk says Saxenda obesity drug to cost $1,068 per month Apr 22 2015
      3 Large-Cap Pharmaceutical Companies to Invest in Right Now Apr 22 2015
      Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog Apr 13 2015
      Novo Nordisk's Tresiba & Ryzodeg NDAs under FDA Review - Analyst Blog Apr 09 2015
      FDA accepts Novo Nordisk's resubmitted application for insulin drug Apr 07 2015
      Hedge Funds Made A Bundle By Betting On Amazon.com, Inc. (AMZN), Apple, and Pfizer Inc Apr 01 2015
      FDA Urged to Fine Drugmakers Over Ads Apr 01 2015
      Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 March 2015) Apr 01 2015
      Top First Quarter European ETFs Mar 31 2015
      The Best and Worst Medalists of 2015's First Quarter Mar 30 2015
      Novo Nordisk’s Insulin Move Is Right Medicine Mar 29 2015
      Colgate-Palmolive Company (CL), Novo Nordisk A/S (ADR) (NVO) Among Billionaire Jim Simons’... Mar 27 2015
      Novo Nordisk to Submit Interim DEVOTE Data to the FDA - Analyst Blog Mar 27 2015
      Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog Mar 27 2015
      Can The Uptrend Continue for Novo Nordisk (NVO)? - Tale of the Tape Mar 27 2015
      March 27 Premarket Briefing: 10 Things You Should Know Mar 27 2015
      Cruise news you can use, plus more Friday business headlines Mar 27 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      Gintaras58
      ReplyGintaras58 - 1 year ago
      few excellent prducts to come soon
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK